sHLA-G levels in the monitoring of immunosuppressive therapy and rejection following heart transplantation

被引:29
|
作者
Luque, J.
Torres, M. I.
Aumente, M. D.
Lozano, J. M.
Garcia-Jurado, G.
Gonzalez, R.
Alvarez-Lopez, M. R.
Arizon, J. M.
Pena, J.
机构
[1] Reina Sofia Univ Hosp, Serv Immunol, Cordoba 14004, Spain
[2] Reina Sofia Univ Hosp, Serv Pharm, Cordoba 14004, Spain
[3] Virgen Arraixaca Hosp, Serv Immunol, Murcia, Spain
[4] Reina Sofia Univ Hosp, Serv Cardiol, Cordoba 14004, Spain
关键词
sHLA-G; heart transplantation; cyclosporine; tolerance; immunosuppressive treatment; LEUKOCYTE ANTIGEN-G; SOLUBLE HLA-G; GRAFT ACCEPTANCE; G EXPRESSION; CELLS; MOLECULE; CD8;
D O I
10.1016/j.trim.2006.09.009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The aim of this study was to further determine the immediate influence, over a 12-h period, after the initiation of daily immunosuppressive treatment on the serum levels of sHLA-G in heart transplant patients during the post-transplant period (1 month). It was found that there are two patterns of patients in term of the changes observed in their levels of sHLA-G in response to the immunosuppressive treatment. One group (group A) showed no changes on sHLA-G while the other group (group B) a significant rise in sHLA-G levels was observed at 2 to 4 h post dose. Interestingly, it was observed that the patients in group B have better prognosis of acceptance of the heart graft than those of group A. On the other hand it was found that the patients with high levels of sHLA-G (77.3 +/- 34.8 ng/ml) in pre-transplant sera have a better prognosis of acceptance of the heart graft than those with low sHLA-G levels (9.7 +/- 7.1 ng/ml). In conclusion, both the intensity of changes of sHLA-G levels induced by immunosuppression and basal levels in pre-transplant could be used in the monitoring of the immunosuppression as well as the heart transplant evolution. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:70 / 73
页数:4
相关论文
共 50 条
  • [21] Evaluation of Maternal Serum sHLA-G Levels for Trisomy 18 Fetuses Screening at Second Trimester
    Xu, Danping
    Zhu, Yiyang
    Li, Lanfang
    Xu, Yingping
    Yan, Weihua
    Dai, Meizhen
    Gan, Linghong
    FRONTIERS IN GENETICS, 2021, 11
  • [22] Increased sHLA-G serum level in melanoma patients and further enhancement by interferon-α therapy
    Ugurel, S
    Rebmann, V
    Ferrone, S
    Tilgen, W
    Grosse-Wilde, H
    Reinhold, U
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (03) : 556 - 556
  • [23] Correlation of serum sHLA-G levels with cyst stage in patients with cystic echinococcosis: is it an immune evasion strategy?
    Mariconti, M.
    Meroni, V.
    Badulli, C.
    Brunetti, E.
    Tinelli, C.
    De Silvestri, A.
    Tamarozzi, F.
    Genco, F.
    Casulli, A.
    Martinetti, M.
    PARASITE IMMUNOLOGY, 2016, 38 (07) : 414 - 418
  • [24] The Relationship between the HLA-G Polymorphism and sHLA-G Levels in Parental Pairs with High-Risk Pregnancy
    Sipak, Olimpia
    Ryl, Aleksandra
    Grzywacz, Anna
    Laszczynska, Maria
    Zimny, Malgorzata
    Karakiewicz, Beata
    Rotter, Iwona
    Kosik-Bogacka, Danuta
    Cybulski, Cezary
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2019, 16 (09)
  • [25] Serum sHLA-G levels: a useful indicator in distinguishing colorectal cancer from benign colorectal diseases
    Zhu, Cheng-Bao
    Wang, Chuan-Xin
    Zhang, Xin
    Zhang, Jian
    Li, Wei
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (03) : 617 - 622
  • [26] DIFFERENCES ON THE HLA-G 3′UTR GENETIC VARIABILITY AND BONE MARROW sHLA-G LEVELS AT DIAGNOSIS AND AFTER INDUCTION THERAPY IN CHILDHOOD ACUTE LEUKEMIA
    Almeida, Renata Dos Santos
    De Luna Ramos, Alessandra Maria
    Vinhas Marques, Ester Augusta
    Pedrosa, Francisco
    Donadi, Eduardo Antonio
    Lucena-Silva, Norma
    TISSUE ANTIGENS, 2015, 86 (02): : 82 - 82
  • [27] Advances of immunosuppressive therapy for heart transplantation
    Lietz, Katherine
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 2 (04) : 18 - 22
  • [28] SOLUBLE HUMAN LEUKOCYTE ANTIGEN G (SHLA-G) IN HEMATOPOIETIC CELL TRANSPLANTATION IS ASSOCIATED WITH SEVERAL CLINICAL COMPLICATIONS AFTER TRANSPLANT
    Waterhouse, M.
    Duque-Afonso, J.
    Samek, E.
    Bertz, H.
    Finke, J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S312 - S313
  • [29] Infectious Risk of Rejection Therapy Following Heart Transplantation; Can It Be Avoided?
    Kittleson, M.
    Patel, J.
    Dimbil, S.
    Levine, R. J.
    Esmailian, G.
    Shen, A.
    Hage, T.
    Kobashigawa, J. A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 783 - 784
  • [30] What is the Risk of Rejection Following Subtherapeutic CNI Levels After Heart Transplantation?
    Kerr, S.
    Jorgensen, N.
    Hong, B.
    Friedland-Little, J.
    Albers, E.
    Law, Y.
    Kemna, M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S63 - S63